DK1861120T3 - Anvendelse af en influenzavirus og en olie-i-vand-emulsionsadjuvans til at fremkalde CD 4-T-celle- og/eller forstærket B-hukommelsescellereaktion - Google Patents
Anvendelse af en influenzavirus og en olie-i-vand-emulsionsadjuvans til at fremkalde CD 4-T-celle- og/eller forstærket B-hukommelsescellereaktion Download PDFInfo
- Publication number
- DK1861120T3 DK1861120T3 DK06723805.5T DK06723805T DK1861120T3 DK 1861120 T3 DK1861120 T3 DK 1861120T3 DK 06723805 T DK06723805 T DK 06723805T DK 1861120 T3 DK1861120 T3 DK 1861120T3
- Authority
- DK
- Denmark
- Prior art keywords
- influenza
- vaccine
- use according
- oil
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (39)
1. Anvendelse af en influenzavirus eller et antigenpræparat deraf og en olie-i-vand-emulsionsadjuvans til fremstilling af en immunogen sammensætning til vaccination af ældre personer på 65 år og derover mod influenza, hvor olie-i-vand-emulsionen omfatter en metaboliserbar olie, alfa-tokoferol og en emulgator.
2. Anvendelse ifølge krav 1, hvor sammensætningen fremkalder en forstærket CD4 T-celleimmunreaktion mod virussen eller antigensammensætningen hos den ældre person.
3. Anvendelse ifølge krav 1 eller 2, hvor olie-i-vand-emulsionen indeholder oliedråber, hvoraf mindst 70 % med hensyn til størrelse er under 1 pm i diameter.
4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor olie-i-vand-emulsionen indeholder oliedråber, hvoraf mindst 70 % med hensyn til størrelse er under 500 nm i diameter.
5. Anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor olie-i-vand-emulsionen indeholder oliedråber, hvoraf mindst 80 % med hensyn til størrelse er under 300 nm i diameter.
6. Anvendelse ifølge et hvilket som helst af kravene 1 til 5, hvor olie-i-vand-emulsionen indeholder oliedråber, hvoraf mindst 90 % med hensyn til størrelse er i området 120 til 200 nm i diameter.
7. Anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor alfa-tokoferolen er til stede i en mængde på 1,0 % til 20 % af det samlede volumen af den immunogene sammensætning.
8. Anvendelse ifølge krav 7, hvor alfa-tokoferolen er til stede i en mængde på 1,0 % til 5,0 % af det samlede volumen af den immunogene sammensætning.
9. Anvendelse ifølge et hvilket som helst af kravenel til 8, hvor den metaboliserbare olie er squalen.
10. Anvendelse ifølge et hvilket som helst af kravene 1 til 9, hvor den metaboliserbare olie er til stede i en mængde på 0,5 % til 20 % af det samlede volumen af den immunogene sammensætning.
11. Anvendelse ifølge krav 10, hvor metaboliserbar olie er til stede i en mængde på 1,0 % til 10 % af det samlede volumen af den immunogene sammensætning.
12. Anvendelse ifølge krav 11, hvor den metaboliserbare olie er til stede i en mængde på 2,0 % til 6,0 % af det samlede volumen af den immunogene sammensætning.
13. Anvendelse ifølge et hvilket som helst af kravene 1 til 12, hvor olie-i-vand-emulsionen yderligere omfatter en sterol.
14. Anvendelse ifølge krav 13, hvor den yderligere sterol er kolesterol.
15. Anvendelse ifølge et hvilket som helst af kravene 9 til 14, hvor forholdet squalen : alfa-tokoferol er 1 eller derunder.
16. Anvendelse ifølge et hvilket som helst af kravene 1 til 15, hvor emulgatoren er Tween 80.
17. Anvendelse ifølge krav 16, hvor emulgatoren er til stede i en mængde på 0,01 til 5.0 % efter vægt af den immunogene sammensætning.
18. Anvendelse ifølge krav 17, hvor emulgatoren er til stede i en mængde på 0,1 til 2.0 % efter vægt af den immunogene sammensætning.
19. Anvendelse ifølge et hvilket som helst af kravene 1 til 18, hvor olie-i-vand-emulsionsadjuvansen har følgende sammensætning: fra 2-10 % squalen, fra 2-10 % alfa-tokoferol og fra 0,3-3 % Tween 80.
20. Anvendelse ifølge et hvilket som helst af kravene 1 til 19, hvor den immunogene sammensætning yderligere omfatter en TLR-4-ligand.
21. Anvendelse ifølge krav 20, hvor TLR-4-liganden er udvalgt fra listen bestående af: et ikke-toksisk derivat af lipid A såsom 3D-MPL; et syntetisk derivat af lipid A; MDP; og RSV F-protein.
22. Anvendelse ifølge krav 21, hvor lipid a-derivatet er 3D-MPL.
23. Anvendelse ifølge krav 22, hvor 3D-MPL er til stede i en mængde på 10 til 50 pg (vægt/volumen) per sammensætningsdosis.
24. Anvendelse ifølge krav 23, hvor 3D-MPL er til stede i en mængde på cirka 25 pg (vægt/volumen) per sammensætningsdosis.
25. Anvendelse ifølge et hvilket som helst af kravene 1 til 24, hvor indgiften af den immunogene sammensætning desuden fremkalder både en forstærket CD4 T-celleimmunreaktion og en forstærket B-hukommelsescellereaktion.
26. Anvendelse af en influenzavirus eller et antigent præparat deraf til fremstilling af en immunogen sammensætning til revaccination of ældre personer på 65 år og derover, som tidligere er blevet vaccineret med en influenzavirus eller et antigent præparat deraf og en olie-i-vand-emulsionsadjuvans omfattende en metaboliserbar olie, alfa-tokoferol og en emulgator, hvor den immunogene sammensætning til revaccination indeholder en fragmenteret influenzavirus eller et fragmenteret virusantigenpræparat deraf, som deler mindst en af i) fælles CD4-T-celle-epitoper, ii) fælles B-celle-epitoper, med influenzavirussen eller det antigene præparat deraf, der blev anvendt til den første vaccination.
27. Anvendelse ifølge krav 26, hvor sammensætningen, der anvendes til revaccination, indeholder en adjuvans.
28. Anvendelse ifølge krav 27, hvor adjuvansen er udvalgt fra listen bestående af: olie-i-vand-emulsionsadjuvans, aluminiumadjuvans, en TLR-4-ligand, en saponin.
29. Anvendelse ifølge et hvilket som helst af kravene 26 til 28, hvor olie-i-vand-emulsionsadjuvansen er som defineret i et hvilket som helst af kravene 1 og 3 til 19, og TLR-4-liganden er som defineret i et hvilket som helst af kravene 21-24.
30. Anvendelse ifølge et hvilket som helst af kravene 26 til 29, hvor den immunologiske reaktion efter revaccination er en, to eller alle af følgende: forstærket CD4-reaktion mod influenzavirussen eller det antigene præparat deraf, eller forstærket humoral reaktion eller forstærket B-cellehukommelsesreaktion.
31. Anvendelse ifølge et hvilket som helst af kravene 1 til 30, hvor influenzavirussen eller det antigene præparat deraf er monovalent, bivalent eller trivalent.
32. Anvendelse ifølge et hvilket som helst af kravene 1 til 31, hvor influenzavirussen eller det antigene præparat deraf er fra tre forskellige influenzastammer.
33. Anvendelse ifølge krav 32, hvor mindst en stamme er forbundet med et pande-misk udbrud eller har potentiale til at blive forbundet med et pandemisk udbrud.
34. Anvendelse ifølge krav 33, hvor den pandemiske stamme er udvalgt fra listen bestående af: H5N1, H9N2, H7N7, H2N2 og H1N1.
35. Anvendelse ifølge et hvilket som helst af kravene 26 til 34, hvor den første vaccination foretages med en fragmenteret influenzasammensætning indeholdende en influenzastamme, som potentielt kunne forårsage et pandemisk udbrud, og revaccinationen foretages med en cirkulerende pandemisk stamme.
36. Anvendelse ifølge et hvilket som helst af kravene 1 til 35, hvor den immunogene sammensætning indeholder en lav dosis HA-antigen.
37. Anvendelse ifølge et hvilket som helst af kravene 1 til 36, hvor influenzaantigenet eller det antigene præparat deraf er æggeafledt eller vævskulturafledt.
38. Anvendelse ifølge et hvilket som helst af kravene 1 til 37, hvor influenzavirussen er udvalgt fra listen bestående af: en fragmenteret influenzavirus, en hel influenzavirus, en underenhed-influenzavirus, et influenzavirosom, og antigent præparat deraf.
39. Anvendelse ifølge krav 38, hvor influenzavirussen er et fragmenteret influenzavi-rusantigen eller antigenpræparat deraf.
Applications Claiming Priority (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0506001A GB0506001D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
GB0506004A GB0506004D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
GB0506000A GB0506000D0 (en) | 2005-03-23 | 2005-03-23 | Novel use |
GB0505998A GB0505998D0 (en) | 2005-03-23 | 2005-03-23 | Novel compositions |
GB0505989A GB0505989D0 (en) | 2005-03-23 | 2005-03-23 | Compositions |
GB0510596A GB0510596D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
GB0510591A GB0510591D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
GB0510589A GB0510589D0 (en) | 2005-05-24 | 2005-05-24 | Novel use |
GB0510598A GB0510598D0 (en) | 2005-05-24 | 2005-05-24 | Composition |
GB0510593A GB0510593D0 (en) | 2005-05-24 | 2005-05-24 | Novel compositions |
GB0603788A GB0603788D0 (en) | 2006-02-24 | 2006-02-24 | Novel composition |
GB0603790A GB0603790D0 (en) | 2006-02-24 | 2006-02-24 | Composition |
GB0603789A GB0603789D0 (en) | 2006-02-24 | 2006-02-24 | Novel use |
PCT/EP2006/002836 WO2006100109A1 (en) | 2005-03-23 | 2006-03-21 | Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1861120T3 true DK1861120T3 (da) | 2016-07-25 |
Family
ID=36441219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06723805.5T DK1861120T3 (da) | 2005-03-23 | 2006-03-21 | Anvendelse af en influenzavirus og en olie-i-vand-emulsionsadjuvans til at fremkalde CD 4-T-celle- og/eller forstærket B-hukommelsescellereaktion |
Country Status (24)
Country | Link |
---|---|
US (5) | US20090081253A1 (da) |
EP (4) | EP1863529A1 (da) |
JP (4) | JP5869744B2 (da) |
KR (5) | KR20160064249A (da) |
AR (3) | AR053833A1 (da) |
AU (3) | AU2006226459A1 (da) |
CA (3) | CA2601022C (da) |
CY (1) | CY1117874T1 (da) |
DK (1) | DK1861120T3 (da) |
EA (3) | EA011419B1 (da) |
ES (1) | ES2585810T3 (da) |
HR (1) | HRP20160816T1 (da) |
HU (1) | HUE027837T2 (da) |
IL (3) | IL185906A0 (da) |
MA (3) | MA30298B1 (da) |
MX (3) | MX2007011748A (da) |
NO (3) | NO20074635L (da) |
NZ (2) | NZ561823A (da) |
PE (3) | PE20061428A1 (da) |
PL (1) | PL1861120T3 (da) |
PT (1) | PT1861120T (da) |
SI (1) | SI1861120T1 (da) |
TW (3) | TW200700078A (da) |
WO (3) | WO2006100110A1 (da) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2457100A (en) * | 1999-02-26 | 2000-09-14 | Chiron S.P.A. | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US20100221284A1 (en) * | 2001-05-30 | 2010-09-02 | Saech-Sisches Serumwerk Dresden | Novel vaccine composition |
DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
US20090081253A1 (en) * | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
US11707520B2 (en) | 2005-11-03 | 2023-07-25 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
JP5363107B2 (ja) * | 2005-11-04 | 2013-12-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル | アジュバントを含むスプリットインフルエンザワクチンにおけるth1/th2バランスの変化 |
AU2006310337B9 (en) * | 2005-11-04 | 2013-11-28 | Novartis Ag | Adjuvanted influenza vaccines including cytokine-inducing agents |
BRPI0618254A2 (pt) * | 2005-11-04 | 2011-08-23 | Novartis Vaccines & Diagnostic | emulsões com agente tensoativo de fase aquosa livre para fornecer adjuvante às vacinas contra influenza dividido |
US10842867B2 (en) | 2005-11-04 | 2020-11-24 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
FR2896162B1 (fr) * | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
AU2007224034B2 (en) | 2006-03-07 | 2012-03-29 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
JP2009534303A (ja) * | 2006-03-24 | 2009-09-24 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー | 冷蔵しないインフルエンザワクチンの保存 |
WO2007144772A2 (en) | 2006-06-15 | 2007-12-21 | Novartis Ag | Adjuvant-sparing multi-dose influenza vaccination regimen |
CA2583555C (en) * | 2006-07-17 | 2020-01-07 | Glaxosmithkline Biologicals S.A. | Influenza vaccine |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
PL2422810T3 (pl) * | 2006-07-17 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
PL2086582T3 (pl) * | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
MX2009003325A (es) | 2006-10-12 | 2009-04-09 | Glaxosmithkline Biolog Sa | Vacuna que comprende un adyuvante de emulsion de aceite en agua. |
GB0622282D0 (en) * | 2006-11-08 | 2006-12-20 | Novartis Ag | Quality control methods |
EP1923070A1 (en) * | 2006-11-15 | 2008-05-21 | Intervet International BV | Vaccine for vaccinating feline against influenza virus |
EA200900784A1 (ru) * | 2006-12-06 | 2009-12-30 | Новартис Аг | Вакцины, включающие антиген из четырех штаммов вируса гриппа |
EP1938835A1 (en) * | 2006-12-29 | 2008-07-02 | Pevion Biotech AG | Non-specific immunostimulating agents |
NZ579262A (en) * | 2007-02-23 | 2012-04-27 | Baylor Res Inst | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
AU2008310312B2 (en) * | 2007-10-12 | 2013-12-19 | Csl Limited | Method of eliciting an immune response against pandemic influenza virus |
DK2200642T3 (da) | 2007-10-19 | 2012-07-16 | Novartis Ag | Meningococvaccinepræparater |
GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
CA2707247A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
US8466259B2 (en) * | 2007-12-07 | 2013-06-18 | National Health Research Institutes | Adjuvants |
TWI376385B (en) * | 2007-12-07 | 2012-11-11 | Nat Health Research Institutes | Production of lipidated proteins in e. coli |
EP2889042A3 (en) * | 2008-03-18 | 2015-10-14 | Novartis AG | Improvements in preparation of influenza virus vaccine antigens |
WO2009128949A2 (en) | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Compositions of dengue viral proteins and methods of use |
GB0905570D0 (en) * | 2009-03-31 | 2009-05-13 | Novartis Ag | Combined vaccines |
US9421251B2 (en) | 2008-06-25 | 2016-08-23 | Novartis Ag | Rapid responses to delayed booster immunisations |
AU2015203072B2 (en) * | 2009-02-10 | 2017-05-25 | Seqirus UK Limited | Influenza vaccine regimens for pandemic-associated strains |
ES2608841T3 (es) | 2009-02-10 | 2017-04-17 | Seqirus UK Limited | Vacunas contra la gripe con cantidades reducidas de escualeno |
WO2010092476A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
US8287880B2 (en) * | 2009-06-02 | 2012-10-16 | National Health Research Institutes | Lipidated vaccine against dengue virus infection |
EP2445927B1 (en) * | 2009-06-22 | 2014-04-23 | National Health Research Institutes | Lipidated tumor- associated antigens and immunotherapeutic compositions |
EP2289575B1 (de) * | 2009-08-06 | 2017-07-05 | Biotronik VI Patent AG | Medizinisches Implantat enthaltend eine antioxidative Substanz |
JP5911799B2 (ja) * | 2009-08-12 | 2016-04-27 | シグモイド・ファーマ・リミテッドSigmoid Pharma Limited | ポリマーマトリックスおよび油相を含んで成る免疫調節組成物 |
EP2308506A1 (en) * | 2009-10-02 | 2011-04-13 | Mucosis B.V. | Adjuvanted intranasal vaccine formulations |
GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
GB0919117D0 (en) | 2009-10-30 | 2009-12-16 | Glaxosmithkline Biolog Sa | Process |
AU2010325748B2 (en) * | 2009-12-03 | 2014-04-17 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
DE102009056884B4 (de) | 2009-12-03 | 2021-03-18 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
CL2012001399A1 (es) | 2009-12-03 | 2013-03-08 | Novartis Ag | Metodo para fabricar adyuvante para vacuna (emulsion aceite/agua con escualeno, polisorbato 80 y trioleato de sorbitan), que comprende (i) formar primera emulsion en homogenizador desde un contendor a otro para formar segunda emulsion, (ii) y microfluidizar primera emulsion para formar segunda emulsion. |
DE102009056871A1 (de) * | 2009-12-03 | 2011-06-22 | Novartis AG, 4056 | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
BR112012013427B8 (pt) | 2009-12-03 | 2021-05-25 | Novartis Ag | circulação dos componentes durante a homogeneização de emulsões |
DE102009056883B4 (de) | 2009-12-03 | 2012-08-16 | Novartis Ag | Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben |
NZ600254A (en) * | 2009-12-03 | 2013-10-25 | Novartis Ag | Arranging interaction and back pressure chambers for microfluidization |
AU2013202690B2 (en) * | 2009-12-03 | 2016-02-11 | Novartis Ag | Hydrophilic filtration during manufacture of vaccine adjuvants |
KR20120107121A (ko) * | 2009-12-22 | 2012-09-28 | 사노피 파스퇴르 리미티드 | 면역원성 조성물 |
AU2011203740B2 (en) * | 2010-01-06 | 2014-11-13 | Vaxinnate Corporation | Methods and compositions for providing protective immunity in the elderly |
WO2011088451A1 (en) * | 2010-01-15 | 2011-07-21 | Novavax, Inc. | Uses of influenza virus-like particles (vlps) for characterization of neuraminidase and hemagglutinin activity |
RU2527688C2 (ru) * | 2010-02-27 | 2014-09-10 | Общество С Ограниченной Ответственностью "Научно-Производственная Фирма "Материа Медика Холдинг" | Способ лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностого антигена н1n1 и лекарственное средство для лечения инфекционных заболеваний, вызванных вирусом гриппа с типом поверхностного антигена н1n1 |
GB201009671D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009676D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
GB201009673D0 (en) | 2010-06-10 | 2010-07-21 | Glaxosmithkline Biolog Sa | Novel process |
US9821051B1 (en) | 2010-10-28 | 2017-11-21 | Seqirus UK Limited | Reducing hospitalization in elderly influenza vaccine recipients |
TW201221642A (en) | 2010-11-15 | 2012-06-01 | Nat Health Research Institutes | Method of producing lipidated polypeptides |
TWI507413B (zh) * | 2010-11-15 | 2015-11-11 | Nat Health Research Institutes | 脂質化多抗原表位疫苗 |
WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
MY173503A (en) * | 2012-12-28 | 2020-01-29 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Nasal influenza vaccine composition |
SG11201509265SA (en) * | 2013-05-10 | 2015-12-30 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
US10080792B2 (en) * | 2013-09-23 | 2018-09-25 | Engen Bio, Inc. | Influenza vaccine and therapy |
CN104436157A (zh) * | 2013-09-23 | 2015-03-25 | 恩金生物有限公司 | 流感疫苗和治疗 |
WO2016046799A1 (en) | 2014-09-26 | 2016-03-31 | Seqirus UK Limited | Vaccination of immunocompromised subjects |
WO2019108928A1 (en) * | 2017-11-30 | 2019-06-06 | Ohio State Innovation Foundation | Mucoadhesive nanoparticle entrapped influenza virus vaccine delivery system |
CN113993542A (zh) * | 2019-01-30 | 2022-01-28 | 葛兰素史密丝克莱恩生物有限公司 | 用于自乳化的油/表面活性剂混合物 |
MX2022007691A (es) * | 2019-12-20 | 2022-07-19 | Fresenius Kabi Austria Gmbh | Metodo para producir emulsiones aceite en agua. |
RU2741003C1 (ru) * | 2020-03-27 | 2021-01-22 | Евгений Дмитриевич Некрасов | Способ производства четырехвалентной субъединичной вакцины против гриппа без адъювантов |
EP4171629A1 (en) | 2020-06-29 | 2023-05-03 | GlaxoSmithKline Biologicals S.A. | Adjuvants |
BR112023002804A2 (pt) | 2020-08-24 | 2023-03-14 | Sanofi Pasteur Inc | Vacinas para covid-19 com adjuvantes em emulsão de esqualeno contendo tocoferol |
AU2021333572A1 (en) | 2020-08-24 | 2023-05-04 | Sanofi Pasteur Inc. | Vaccines against sars-cov-2 infections |
KR102270165B1 (ko) | 2020-10-22 | 2021-06-28 | 한국화학연구원 | 세정제 조성물 |
US20240165224A1 (en) | 2021-03-26 | 2024-05-23 | Glaxosmithkline Biologicals Sa | Immunogenic compositions |
WO2023274860A1 (en) | 2021-06-28 | 2023-01-05 | Glaxosmithkline Biologicals Sa | Novel influenza antigens |
RU2766292C1 (ru) * | 2021-08-05 | 2022-03-14 | Федеральное государственное унитарное предприятие "Санкт-Петербургский научно-исследовательский институт вакцин и сывороток и предприятие по производству бактерийных препаратов" Федерального медико-биологического агентства (ФГУП СПбНИИВС ФМБА России) | Состав вакцины против covid-19 |
WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
WO2023061993A1 (en) | 2021-10-13 | 2023-04-20 | Glaxosmithkline Biologicals Sa | Polypeptides |
Family Cites Families (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3095974A (en) * | 1961-10-27 | 1963-07-02 | Anthony R Perini | Collapsible book rack |
US4047869A (en) * | 1973-02-23 | 1977-09-13 | Mulvany Jr R F | Apparatus for forming plastic articles |
FR2333610A1 (fr) * | 1975-12-03 | 1977-07-01 | Zhdanovsky Z Tyazhelogo Mash | Bande-electrode a ame en poudre pour rechargement a l'aide d'un alliage resistant a l'usure |
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
DD155875A1 (de) | 1980-12-31 | 1982-07-14 | Willy Nordheim | Verfahren zur herstellung eines ballaststoffarmen inaktivierten influenzaimpfstoffes |
US4436727A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
DD211444A3 (de) | 1982-08-19 | 1984-07-11 | Saechsisches Serumwerk | Verfahren zur herstellung von influenza-impfstoffen |
GB8300467D0 (en) | 1983-01-08 | 1983-02-09 | Wellcome Found | Equine influenza |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
DD300833A7 (de) | 1985-10-28 | 1992-08-13 | Saechsische Landesgewerbefoerd | Verfahren zur herstellung von inaktivierten influenza-vollvirusimpfstoffen |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
WO1988009797A1 (en) | 1987-06-05 | 1988-12-15 | The United States Of America, As Represented By Th | Autocrine motility factors in cancer diagnosis and management |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
DE3734306A1 (de) | 1987-10-10 | 1989-04-27 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung fuer fliessfaehige medien |
US5376369A (en) * | 1987-11-03 | 1994-12-27 | Syntex (U.S.A.) Inc. | Vaccine adjuvant |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8821049D0 (en) | 1988-09-08 | 1988-10-05 | Health Lab Service Board | Method & composition for treatment & prevention of viral infections |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
ES2068989T3 (es) * | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoles como adyuvante en vacunas. |
US5092235A (en) | 1989-05-24 | 1992-03-03 | Tektronix, Inc. | Pressure fixing and developing apparatus |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
DE4005528C2 (de) | 1990-02-22 | 1998-01-15 | Pfeiffer Erich Gmbh & Co Kg | Austragvorrichtung für Medien |
US5969109A (en) * | 1990-02-28 | 1999-10-19 | Bona; Constantin | Chimeric antibodies comprising antigen binding sites and B and T cell epitopes |
WO1991013261A1 (en) | 1990-03-02 | 1991-09-05 | Experimentalny Nauchno-Issledovatelsky Institut Metallorezhuschikh Stankov | Digital servo drive |
US5149531A (en) * | 1990-06-27 | 1992-09-22 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
GB9105992D0 (en) | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
MA22842A1 (fr) | 1992-03-27 | 1993-10-01 | Smithkline Beecham Biolog | Procede de preparation de compositions de vaccin. |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
AU6141094A (en) | 1993-02-19 | 1994-09-14 | Smithkline Beecham Biologicals (Sa) | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
CN1124013A (zh) * | 1993-02-19 | 1996-06-05 | 史密丝克莱恩比彻姆公司 | 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物 |
EP1175912A1 (en) | 1993-03-23 | 2002-01-30 | SmithKline Beecham Biologics SA | Vaccine compositions containing 3-O deacylated monophosphoryl lipid A |
US5762939A (en) * | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
SI0729473T1 (en) | 1993-11-17 | 2001-02-28 | Om Pharma | Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
ATE280585T1 (de) | 1994-02-24 | 2004-11-15 | Micro Pak Inc | Impfstoffe, die paucilamelläre lipidvesikel als adjuvans enthalten |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
US5916879A (en) | 1996-11-12 | 1999-06-29 | St. Jude Children's Research Hospital | DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof |
TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
CA2302554C (en) * | 1997-09-05 | 2007-04-10 | Smithkline Beecham Biologicals S.A. | Oil in water emulsions containing saponins |
GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
CA2324289C (en) * | 1998-03-09 | 2010-07-13 | Smithkline Beecham Biologicals S.A. | Combined vaccine compositions |
US6838269B1 (en) * | 1998-04-15 | 2005-01-04 | Genencor International, Inc. | Proteins producing an altered immunogenic response and methods of making and using the same |
NZ508013A (en) | 1998-05-07 | 2003-08-29 | Corixa Corp | Adjuvant composition for use with an antigen in a vaccine composition |
WO1999064301A1 (fr) | 1998-06-08 | 1999-12-16 | Sca Emballage France | Emballage a remise a plat rapide |
ATE355266T1 (de) | 1998-06-30 | 2006-03-15 | Om Pharma | Neue acylierte pseudodipeptide, verfahren zu ihrer herstellung, und diese enthaltende pharmazeutische zusammensetzungen |
AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
US20040006242A1 (en) | 1999-02-01 | 2004-01-08 | Hawkins Lynn D. | Immunomodulatory compounds and method of use thereof |
US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
AT407958B (de) | 1999-02-11 | 2001-07-25 | Immuno Ag | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation |
AU2875700A (en) | 1999-02-26 | 2000-09-14 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
FR2796289B1 (fr) | 1999-07-16 | 2001-08-10 | Cross Site Technologies | Seringue sans aiguille avec injecteur a elements superposes |
FR2796291B1 (fr) | 1999-07-16 | 2001-09-21 | Cross Site Technologies | Seringue sans aiguille munie d'un systeme de declenchement piezo-electrique |
FR2796290B1 (fr) | 1999-07-16 | 2001-09-14 | Cross Site Technologies | Seringue sans aiguille fonctionnant avec un generateur d'onde de choc a travers une paroi |
GB9921147D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
GB9923176D0 (en) * | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
FR2800619B1 (fr) | 1999-11-05 | 2002-02-08 | Cross Site Technologies | Seringue sans aiguille avec un moyen de poussee temporairement retenu |
FR2802102B1 (fr) | 1999-12-08 | 2002-07-12 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un tube d'ejection a section constante |
FR2802103B1 (fr) | 1999-12-08 | 2003-10-03 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec entrainement du principe actif par effet tube a choc |
AU1581400A (en) | 1999-12-22 | 2001-07-03 | Om Pharma | Acyl pseudopeptides bearing a functionalised auxiliary spacer |
FR2802820B1 (fr) | 1999-12-27 | 2002-10-18 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par effet tube a choc, avec maintien prealable du principe actif sur le cote |
CN1326873C (zh) | 2000-01-31 | 2007-07-18 | 史密丝克莱恩比彻姆生物有限公司 | 用于hiv预防或治疗性免疫的疫苗 |
FR2804329B1 (fr) | 2000-02-02 | 2002-12-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un opercule contenant le principe actif |
FR2804869B1 (fr) | 2000-02-11 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille pour l'injection d'un liquide contenu dans une ampoule pre-remplie |
FR2805749B1 (fr) | 2000-03-01 | 2002-05-17 | Poudres & Explosifs Ste Nale | Seringue sans aiguille a deux niveaux de vitesse d'injection |
FR2807946B1 (fr) | 2000-04-19 | 2002-06-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant avec un chargement pyrotechnique bicomposition |
FR2809626B1 (fr) | 2000-05-30 | 2003-03-07 | Poudres & Explosifs Ste Nale | Seringue sans aiguille avec membrane d'isolation d'un ejecteur multiconduit |
FR2810554B1 (fr) | 2000-06-22 | 2003-05-16 | Poudres & Explosifs Ste Nale | Seringue sans aiguille munie d'un reservoir modulable |
FR2812202B1 (fr) | 2000-07-28 | 2002-09-13 | Poudres & Explosifs Ste Nale | Seringue sans aiguille fonctionnant par mise en compression du reservoir contenant le principe actif liquide |
GB0025577D0 (en) * | 2000-10-18 | 2000-12-06 | Smithkline Beecham Biolog | Vaccine |
FR2815544B1 (fr) | 2000-10-23 | 2003-02-14 | Poudres & Explosifs Ste Nale | Seringue sans aiguille securisee a architecture compacte |
EP1201250A1 (en) | 2000-10-25 | 2002-05-02 | SMITHKLINE BEECHAM BIOLOGICALS s.a. | Immunogenic compositions comprising liver stage malarial antigens |
EP2269639B1 (en) * | 2001-02-23 | 2018-11-28 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
MY134424A (en) * | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US6861410B1 (en) | 2002-03-21 | 2005-03-01 | Chiron Corporation | Immunological adjuvant compositions |
AU2003224819A1 (en) * | 2002-04-01 | 2003-10-20 | Euro-Celtique S.A. | Epitope constructs comprising antigen presenting cell targeting mechanisms |
ATE426412T1 (de) | 2003-01-30 | 2009-04-15 | Novartis Vaccines & Diagnostic | Adjuvante influenza-vakzine |
US20080254065A1 (en) * | 2004-03-09 | 2008-10-16 | Chiron Corporation | Influenza Virus Vaccines |
US20090028903A1 (en) * | 2005-03-23 | 2009-01-29 | Glaxosmithkline Biologicals, S.A. | Novel use |
US20090081253A1 (en) * | 2005-03-23 | 2009-03-26 | Glaxosmithkline Biologicals S.A. | Composition |
AR054822A1 (es) | 2005-07-07 | 2007-07-18 | Sanofi Pasteur | Emulsion inmuno adyuvante |
NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
WO2007130330A2 (en) | 2006-05-01 | 2007-11-15 | Technovax, Inc. | Polyvalent influenza virus-like particle (vlp) compositions |
PL2422810T3 (pl) * | 2006-07-17 | 2015-03-31 | Glaxosmithkline Biologicals Sa | Szczepionka przeciw grypie |
MX2009000660A (es) | 2006-07-17 | 2009-04-08 | Glaxosmithkline Biolog Sa | Vacuna de influenza. |
MX2009003325A (es) * | 2006-10-12 | 2009-04-09 | Glaxosmithkline Biolog Sa | Vacuna que comprende un adyuvante de emulsion de aceite en agua. |
TW200908994A (en) * | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
CA2707247A1 (en) * | 2007-12-06 | 2009-06-11 | Glaxosmithkline Biologicals S.A. | Influenza composition |
-
2006
- 2006-03-21 US US11/909,414 patent/US20090081253A1/en not_active Abandoned
- 2006-03-21 PL PL06723805.5T patent/PL1861120T3/pl unknown
- 2006-03-21 AR ARP060101106A patent/AR053833A1/es not_active Application Discontinuation
- 2006-03-21 AR ARP060101108A patent/AR052625A1/es unknown
- 2006-03-21 SI SI200632082A patent/SI1861120T1/sl unknown
- 2006-03-21 EA EA200701786A patent/EA011419B1/ru not_active IP Right Cessation
- 2006-03-21 NZ NZ561823A patent/NZ561823A/en not_active IP Right Cessation
- 2006-03-21 AR ARP060101107A patent/AR054020A1/es not_active Application Discontinuation
- 2006-03-21 JP JP2008502344A patent/JP5869744B2/ja active Active
- 2006-03-21 MX MX2007011748A patent/MX2007011748A/es not_active Application Discontinuation
- 2006-03-21 CA CA2601022A patent/CA2601022C/en active Active
- 2006-03-21 EP EP06723806A patent/EP1863529A1/en not_active Withdrawn
- 2006-03-21 KR KR1020167014235A patent/KR20160064249A/ko not_active Application Discontinuation
- 2006-03-21 US US11/909,388 patent/US20080171063A1/en not_active Abandoned
- 2006-03-21 HU HUE06723805A patent/HUE027837T2/en unknown
- 2006-03-21 KR KR1020077024388A patent/KR20070116652A/ko active Search and Examination
- 2006-03-21 AU AU2006226459A patent/AU2006226459A1/en not_active Abandoned
- 2006-03-21 PT PT67238055T patent/PT1861120T/pt unknown
- 2006-03-21 TW TW095109703A patent/TW200700078A/zh unknown
- 2006-03-21 WO PCT/EP2006/002837 patent/WO2006100110A1/en active Application Filing
- 2006-03-21 WO PCT/EP2006/002838 patent/WO2006100111A1/en active Application Filing
- 2006-03-21 DK DK06723805.5T patent/DK1861120T3/da active
- 2006-03-21 ES ES06723805.5T patent/ES2585810T3/es active Active
- 2006-03-21 CA CA2603180A patent/CA2603180C/en active Active
- 2006-03-21 NZ NZ561822A patent/NZ561822A/en not_active IP Right Cessation
- 2006-03-21 JP JP2008502345A patent/JP5770414B2/ja active Active
- 2006-03-21 MX MX2007011775A patent/MX2007011775A/es not_active Application Discontinuation
- 2006-03-21 JP JP2008502346A patent/JP2008534467A/ja active Pending
- 2006-03-21 PE PE2006000312A patent/PE20061428A1/es not_active Application Discontinuation
- 2006-03-21 AU AU2006226458A patent/AU2006226458B2/en active Active
- 2006-03-21 EA EA200701785A patent/EA011393B1/ru not_active IP Right Cessation
- 2006-03-21 KR KR1020077024380A patent/KR20070116650A/ko not_active Application Discontinuation
- 2006-03-21 MX MX2007011756A patent/MX2007011756A/es active IP Right Grant
- 2006-03-21 TW TW095109709A patent/TW200700079A/zh unknown
- 2006-03-21 EA EA200701787A patent/EA200701787A1/ru unknown
- 2006-03-21 KR KR1020137034497A patent/KR101916787B1/ko active IP Right Grant
- 2006-03-21 TW TW095109708A patent/TW200722101A/zh unknown
- 2006-03-21 EP EP11173265A patent/EP2397153A1/en not_active Withdrawn
- 2006-03-21 EP EP06723807A patent/EP1861122A1/en not_active Withdrawn
- 2006-03-21 KR KR1020077024383A patent/KR20070116651A/ko not_active Application Discontinuation
- 2006-03-21 EP EP06723805.5A patent/EP1861120B1/en active Active
- 2006-03-21 PE PE2006000311A patent/PE20061300A1/es not_active Application Discontinuation
- 2006-03-21 WO PCT/EP2006/002836 patent/WO2006100109A1/en active Application Filing
- 2006-03-21 AU AU2006226543A patent/AU2006226543B2/en active Active
- 2006-03-21 US US11/909,351 patent/US20080181911A1/en not_active Abandoned
- 2006-03-21 CA CA002602456A patent/CA2602456A1/en not_active Abandoned
- 2006-03-23 PE PE2006000334A patent/PE20061387A1/es not_active Application Discontinuation
-
2007
- 2007-09-11 IL IL185906A patent/IL185906A0/en unknown
- 2007-09-11 IL IL185901A patent/IL185901A0/en unknown
- 2007-09-11 IL IL185897A patent/IL185897A/en active IP Right Grant
- 2007-09-12 NO NO20074635A patent/NO20074635L/no not_active Application Discontinuation
- 2007-09-12 NO NO20074638A patent/NO20074638L/no not_active Application Discontinuation
- 2007-09-24 MA MA30238A patent/MA30298B1/fr unknown
- 2007-09-24 MA MA30241A patent/MA29342B1/fr unknown
- 2007-09-24 MA MA30240A patent/MA29715B1/fr unknown
- 2007-09-28 NO NO20074930A patent/NO20074930L/no not_active Application Discontinuation
-
2011
- 2011-04-28 US US13/096,180 patent/US20110287054A1/en not_active Abandoned
-
2014
- 2014-01-31 JP JP2014016254A patent/JP2014129359A/ja active Pending
- 2014-08-21 US US14/465,055 patent/US9730999B2/en active Active
-
2016
- 2016-07-07 HR HRP20160816TT patent/HRP20160816T1/hr unknown
- 2016-08-05 CY CY20161100772T patent/CY1117874T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1861120T3 (da) | Anvendelse af en influenzavirus og en olie-i-vand-emulsionsadjuvans til at fremkalde CD 4-T-celle- og/eller forstærket B-hukommelsescellereaktion | |
US11564984B2 (en) | Influenza vaccine | |
US20090028903A1 (en) | Novel use | |
US20070141078A1 (en) | Influenza vaccine | |
US20080014217A1 (en) | Influenza vaccine | |
US20230201329A1 (en) | Influenza vaccine | |
AU2007202129B2 (en) | Influenza vaccine | |
BRPI0609516A2 (pt) | uso de um vìrus de influenza ou preparação antigênica do mesmo e um adjuvante de emulsão de óleo-em-água, e, método para projetar uma vacina para doenças conhecidas por serem curadas ou tratadas por meio de uma ativação de células tcd4+ |